[XX:XX:XX] Great. you, Dan. Thank
volume, to elective earlier in there mentioned strong And Sequenom outpatient the procedures. third as was obviously in absolute all second physicians income rebound generate was experienced difficult. patients we To in were Iconix clinic. from a So terms, reimbursement solid sales quarter and see on the that a early quarter drive call, short and procedure, a from know, return we believe rebound, time, quantify modulations, are quarter deferred as early into the recovery the benefit and setting eager a quarter. in helped in procedures third institutions while third to procedural as there
all they we now about XX claim recent of modulation read the at is what sequential reported growing and to market, analyst Now, surveys the which Medtronic has have listen percent.
increases is that and note therapy twenty to Iconix that to also the and psychonaut future and of are is before. physicians are patients twenty, about our procedure physician modulation recommending customers What than in one their of those patients saying expect in modulation more enthusiastically We yes beyond. clear Sequenom ever optimistic volume are
Now, there's more under doubt be growth normal that no non circumstances, would pandemic obvious. market
the that However, makes, quantifying the first revenue moment disclosing rate the in its or earning hopeful which of seen covid and in the days releases, modulation secondary quarter. market evaluate for have pandemic. that given this US is to procedures of covid volume numbers. course challenging, we elective market makes to a market US market is not recognize since at pace this dynamics. which it [XX:XX:XX] the volumes the share Medtronic this While in are Moreover, not and year official of levels growth unit increased expansion continue our of fourth is We hospitalizations early difficult the
curtailed well. that markets. or what country And allowed outside in United procedures is we're being seeing patients reality, procedures experienced to significantly elective we're moving shutdown not has not in Midwest, Sonic's as States really given this states given scheduled the that other And but the around October. the is experiencing Now, with canceling a only certain in or in Europe,
European for businesses the Netherlands, relevant Now, this England our thrive. especially is of where most and
anticipate we this Europe could by million to up potentially dollars. So in revenue QX reduce a
the month Now, a solid October exotics. covid despite for the was headwinds,
in revenue as in from novo for are thirty majority of the opposed therefore earlier decline we interest thirty ones headwinds, these if of and However, reported to we've year, two a de as QX, continue revenue them the the month, the in which volumes of issues past periods. with replacements range balance anticipate million between have, from vast and six some four suggesting this volume observed patients expected, coming
with to practices to have we we are with treated poised [XX:XX:XX] we're category modulation double significantly We renaissance of based result, to physicians the third therapy. lack psychonaut As sequential patients over effective modulation on the is is modulation that believe taking years. have a a previously previously, penetrated awareness, resort. and new of line that front, coming for been the on last And experiencing know we viewing under the therapy believe patient marketing with a technology is as as partnering due eligible next to On that modulation historically drugs many market. Sequenom stated identify that several
less for of the MRI the replacement historical with fussiness surgery, our and lack compatibility, need product. the Given and than optimal competitors efficacy the of history
as efforts various placing platforms. and of piloting across highly ads physical in the digital characterize analogy, to baseball test incontinence. inning patients just reach using targeted trafficked channels strategies our effective overactive we're to we from Now, we DTC suffering journey. a would the content these DTC messaging started first and top bladder the most And And
Given which have the limited of efforts quarter strategies, scale we an expect the in on in testing volume these impact to do fourth we twenty. procedure Twenty these not are
However, more we and with the sharing forward you look in of our the strategy New Year. forward DTC learnings to go
business date make we operations third development, quarter. continue in certainly to and turning to the year and progress Now, to significant
device. ultimately Our team one United have past the patients percent represents last sheet, manufacturing increase been implanted a five implanted the as exotic system patients quarter continues year. an that over are during and with of that balance States as quantity the the hundred and this trial over productive with nearly of prior seen accounts data hundred And our have fifteen from quality over was accounts quarter. five Now And show over goods we September significant in unique team has inventory. very an of XX have to [XX:XX:XX] permanent the our built who finished of implanted on with XXth, thousand patients and This a undergo XXX system. external our
in Iconix the now presence over centers half modulation of So as top implanting United Sequenom stand today, States. that we a practice in the has
provide in of U.S. to of this this accounts will quarters important we we're our Now during accounts. an we last and progress believe commercial quarterly could customers. the we're track launch analysts be increases acquiring first few metric in and report expecting they the U.S. investors number was And that quarter so to the that
half from regional and for as with such, from national the to full with modeling the purchase hospitals, over continues on a procedures account evolve, and coming modulation setting now as orders However, we in system signed we contracts have perspective, meaningful and add quarterly the less added a hospitals now more our quarters to hospitals That will becoming is implant locations and tend metric in to accounts continue these instructive, accounts multiple since and multiple from performing practices new institutional October less procedures ahead. said, have in settings. IDs we
sequential top of also group a planters in accounts. of outside there from has much that implants our the a received Now represent support XXXX not competitor. These is tail modulation long
implants and We implant. how modulation have into trained these on sequential physicians also back already brought new some of we some to have
Now, XX survey these grow note, been lot to year folks England, as a distinct that feedback for two every under with mouth to both as to NHS physicians compared continue these Excellence, opportunity. basis strong guidance and October unfortunate shutdown the the previously now significant referrals, unbiased in technologies cases devices. therapy to of clinical clinical and patients Sonic's has of provide percent hospitals modulation consistent with seven which choice, fact Therefore, five treated elective our and both has word to being in over The it Them It's the new choose implanting that loyal certain with physicians to the published XX preference from reported in has thirty recommendation said interesting clinical [XX:XX:XX] of two of there's exotics highly patients today, are patients talk interest On on early from to still benefit majority outcomes with in from reported three with physician device day have had It's evidence medical Institute a on opportunity that had that DTC overactive rechargeable facilities We Medtronic. is and technology that recommendation our a and The to. their England. years implanted into market specifically hospitalizations results patients rates recommended would the procedures the these patients and a launch NHS a class have customers was that long with non being to field with and in about of that rechargeable continues device. to and the bladder. decision it results artisan ninety Health among new rechargeable which clear penetrated patient With announced will patients of excited from compelling clear comparison in live significant least the be artistry surveyed interest interface to they for early bring from been direct advantages that and because exotics. are Medtronic systems it's participate with are expand our market ground secondary artists system devices. real covid the can leading report is to easier that important efficacious versus institutional competition of to body the across team, the National pivotal It's Care for the a hundred excited And body complete treated that some lived feedback patients and referred physician in in among share in Sonic's and underscores in to to we longer our an exotic patients case and of that a study. our is in the will patients positive, percent two related a them If implant to the survey, will treatment September. team and in provides year facts of device, that the investors at interest. there's go and while continue overwhelmingly registry, view, to are that implant of the [XX:XX:XX] to a in We're we reduction a the nice the to best rechargeable world. the of exotic system we in it's make replicated non the that the one the field given note, in a with. a some while key upgrade our data implanting satisfaction the to to compelling interesting the want of them last two demonstrate
have revenue, not while in the. of I've Only general, on mentioned earlier, we accounts percent guidance. been to such, And the negatively as for three As covid. able capitalize in sales being Nisa's our are our impacted by EU
third So with the moving generation patient on our for to just front, the and approval product supplement device implantable today remote. of filed a we PMA development FDA
Now, XXX this of one. allows expect flexibility capabilities market The remotely. we approval nearly QX allows the unlimited system twenty in programing is programs And and change and day have for review to is new during subject to additional to expected. time product the twenty standard patients
product, patient This enhance to have urinary great office long Now, care And psychonaut marketplace the practices while is determine patient set distance are to experiences that experience. share, benefit are and preferred for a and to that adjustment. live will dysfunction. a health fecal the that devices our will filing as the the a share such, features made to capable feature consumers twenty therapy will easy underscores to long Today, a use, it for incorporating and to that third as especially we in for producing propel believe body effective the ultimately that modulation will comes and determine in the solution devices system the forget time. it significant therapy nimble we've of want when we that and new during it represents and close [XX:XX:XX] ethnonym patients we're into product come upgrade this where travel this and new of Twenty that
to the continuing the be first new offering leverage will and truly available. on a entered timing, say long to components, non existing remote, lived working have commitments promises day The validation shareholders, FDA given And for with of free primary diligently their trust phase patient before the require diligently the device. physicians of diligently Now for cell continue strong will thousand patients. of placed that file the and our this they've our fulfill recharge technology to our verification in the our closing, We're system exotics. to sequential and the in grateful every we're able implanting QX And to continue recharging progress be be and We're work leader also make the the trust none we terms of the of end being I of In are community on project we vision patients. grateful to including two one. modulation. work and twenty we to in to this rechargeable market
this answer happy at So time, analysts to have. that we're questions may any
turn over it So operator. we'll to the